Background. The elicitation of T-helper type 1 (Th1) cellular immunity to eradicate intracellular pathogens is a challenging task because of the interleukin 12 (IL-12) deficit observed in early infancy.
Vaccination formulation has shifted from early empirical approaches to late, rationally designed strategies that integrate molecularly defined antigens, and adjuvants into vaccines. On this winding road, systems biology approaches have initiated the definition of a comprehensive picture, using high-throughput immune system analyses, which more accurately define protection correlates [1] . The rationale of vaccine design is, however, facing a paucity of immune system knowledge for the main target population that is receiving immunizations: neonates and infants [2] . How the immune system in early life responds to vaccines is barely known and requires assessment to elaborate the next generation of vaccines.
Cellular immune responses to vaccines remain the major knowledge gap and are generally ignored during evaluations of adult vaccination efficacy. This situation is even worse following pediatric vaccination, for obvious practical and ethical reasons. Despite the efficacy of the BCG vaccine in the induction of T-helper type 1 (Th1) responses [3] , newborns are viewed with limited cellular immunity, possibly due to the reduced inflammation to Toll-like receptor (TLR) activation [4] [5] [6] [7] and defective antigen-presenting cell (APC) functions [8] .
TLR7/8 agonists may behave appropriately [9] , although their impact on neonatal interleukin 12 (IL-12) and dendritic cell (DC) functions remains unknown. Emerging subunit vaccines seek molecularly defined, powerful adjuvants with predictable side effects; TLR agonists enter this category but are misfit in the neonatal context, as studies show progressive maturation with age of the IL-12/interferon γ (IFN-γ) response [7, 10] .
We and others have shown that neonatal dendritic cells in the mouse model are not intrinsically defective for innate responses and APC functions [11, 12] . In humans, epigenetic regulation can impair IL-12 response to lipopolysaccharide (LPS) of cord blood monocyte-derived DCs (MoDCs) [13] . CpG/TLR9 activation of neonatal plasmacytoid DCs ( pDCs) could be defective for IFN-α production [14] . To what degree the human neonatal innate and adaptive immune system is immature and/or dysfunctional to elicit IFN-γ cellular immunity is unknown. Exploiting our recent demonstration that isolated neonatal pDCs can efficiently respond to a variety of viruses, including herpes simplex virus type 1, human immunodeficiency virus type 1 (HIV-1), and influenza A virus, we [15] investigated their potential contribution in driving IFN-γ-associated T-cell responses. Under these conditions, but also following CpG activation, neonatal pDCs can produce various chemokines and cytokines, including IFN-α. We thus evaluated their capacity to be mobilized to promote neonatal T-helper cell differentiation into Th1 effectors in vitro. Screening neonatal cord blood responses to various pediatric vaccines, we identified the inactivated trivalent influenza vaccine (TIV) as a Th1-driving adjuvant through pDCs activation in a neonatal setting. On the basis of our findings, we propose that vaccination strategies promoting cellular immunity in early life could be based on the IFN-α/IFN-γ axis rather than on the traditional IL-12/ IFN-γ pathway, which is hardly mobilized in infants.
METHODS

Blood
Heparinized cord blood samples were collected from healthy full-term neonates from Maternity Port Royal and Bichat between 2009 and 2012. Buffy coats from 18-60-year-old donors were obtained from the Établissement Français du Sang. Approval from the Institut Pasteur Review Board for Medical Research and the Regional Ethics Committee CPP IDF IV was obtained to conduct the present study. Cord blood samples were obtained following receipt of written consent from the mothers of participating infants.
Cell Purification pDCs were purified from cord blood mononuclear cells (CBMCs) or adult peripheral blood mononuclear cells, using anti-BDCA-4 magnetic beads and an autoMACS Pro apparatus (Miltenyi Biotec). Enriched pDCs were then FACS sorted
Aria cell sorter (BD). The gating strategy for pDC purification was as we previously published [13] . pDC depletion was performed using BDCA4 magnetic beads, which led to approximately 80% pDC depletion from the CBMC cell fraction. CD4 + naive cord and adult T cells were sorted as 99% of
Media and Reagents
All antibodies were from eBioscience, except those against BDCA-2 (AC144), BDCA-4 (AD5-17F6), and IFN-α (LT27:295), which were from Miltenyi Biotec.
Complete medium consisted of Roswell Park Memorial Institute 1640 containing 5%-10% fetal calf serum and antibiotics (GIBCO BRL). R848 and LPS were from Invivogen. CpG-A (2216; 5′-GGGGACGATCGTCGGGGGG-3′) and CpG-B 
In Vitro T-Cell Differentiation
A total of 250 µL of fresh heparinized cord or adult blood was plated in 96-well flat-bottomed plates and stimulated with the indicated reconstituted vaccines at a ratio of vaccine to blood volume of 1:10. Twenty-four hours later, plasma was collected and tested for cytokines. To determine the effect of vaccine stimulation on T-cell polarization, mononuclear cells from the vaccine-exposed cord blood indicated above were separated by Lymphoprep and were further cultured with Dyna anti-CD3 beads at a ratio of 1:1 for 6 days. The differentiated T cells were restimulated by plate-bound anti-CD3 (10 µg/mL; clone OKT3) and soluble anti-CD28 (0.5 µg/mL; clone CD28. beads at a ratio of 1:1 by using 50% volume of conditioned medium. Six days later, T cells were restimulated with PMA/ Ionomycin for intracellular staining.
Cytokine Measurement
After stimulation, supernatants were harvested and stored at −20°C for further analysis. Cytokines and chemokines were measured using Luminex kits (Biosource) according to the manufacturer's instructions. Prepared samples were run on a Luminex X100 machine and analyzed using Starstation software (Applied Cytometry). Interleukin 22 (IL-22), IL-12p70, and interleukin 23 (IL-23) were measured by an enzyme-linked immunosorbent assay (eBioscience).
Intracellular Cytokine Analyses
For intracellular cytokine staining, after restimulation of T cells with 50 μg/mL PMA (Sigma) and 1 μg/mL Ionomycin (Sigma) in the presence of GolgiPlug (BD) for 5 hours, the cells were treated with Cytofix/Cytoperm and then stained with labeled antibodies against interleukin 2 (IL-2; phycoerythrin [PE]-Cy7), interleukin 4 (IL-4; PE), interleukin 10 (IL-10; PECy7), interleukin 13 (allophycocyanin), interleukin 17 (IL-17), IL-22 (PE), IFN-γ (fluorescein isothiocyanate), and TNF-α (eBioscience) for 30 minutes at 4°C. Cells were detected on a FACSCanto (BD Biosciences) or CyAn (Coulter) machine and analyzed by FlowJo software (Tree Star).
Cross-presentation Assay
Purified neonatal or adult pDCs from HLA-A*02 donors were exposed for 4 hours to 25-300 ng/mL AT-2-inactivated HIV MN (MN-AT2) virus. pDCs were then cocultured for at least 8 hours with the EM-40 CD8 + T-cell clone that is specific for Gag and recognizes the HLA-A*02-restricted SL9 epitope p17 (amino acids 77-85) at a ratio of pDCs to CD8 + T-cell clones of 1:3.
IFN-γ production was measured by the enzyme-linked immunosorbent spot assay to assess cross-presentation.
Statistical Analysis
Unpaired t tests were used to compare 2 groups of data. Data are presented as the mean value ± SD. P values of <.05 were considered statistically significant.
RESULTS
TIV Can Drive a Neonatal Th1 Response in a pDC-Dependent Manner
Neonatal blood was previously shown to be defective for IL-12 in response to LPS [10] . When exposed to LPS/TLR4 and R848/ TLR7 and stimulation with 8 different vaccine formulations, neonatal blood showed a decreased production of IL-12p70, whereas similar amounts of IL-23 were produced (Supplementary Figure 1A and 1B). In these conditions, TLR-dependent IL-12-driven neonatal Th1 differentiation is strongly compromised. BCG vaccine has been shown to be one of the rare vaccines to induce neonatal Th1 responses and, additionally, to induce bystander adjuvant effects that enhance Th1 responses to other neonatal vaccines [16] . We have used a surrogate method to study the adjuvant effects of a panel of vaccines on neonatal T-cell differentiation. Whole cord blood was first stimulated with different pediatric vaccines for 24 hours, then CBMCs were separated and further stimulated with aCD3 beads for 6 days. As expected, BCG vaccine induced IFN-γ-producing T cells in correlation with its capacity to trigger innate IL-12 responses in cord blood ( Figure 1A and 1B). Despite the lack of detectable IL-12p70, this is in agreement with the well-described Th1-inducing capacity of BCG vaccine. One possibility could be that very low levels of IL-12p70 were produced and rapidly consumed by other cells. Interestingly, among the other vaccines, only TIV induced a Th1 differentiation, but it did so independently of innate IL-12 responses ( Figure 1A and 1B and Supplementary Figure 2) . In addition, no innate IFN-γ response was observed in TIVstimulated cord blood ( Figure 1B ). In addition, we observed a similar T-cell cytokine profile following whole cord blood conditioning by TIV and BCG vaccine, including IFN-γ, TNF-α, granulocyte macrophage colony-stimulating factor, and IL-22 ( Figure 1A) . Assessing the innate inflammatory responses of neonatal whole blood, we found that IFN-α but neither IL-12 nor innate IFN-γ was found in response to TIV ( Figure 1B) .
First, we determined the innate response of the IL-12 family to vaccines and then to differentiated T cells by analyzing a large panel of secreted cytokines. Importantly, any of the vaccines was not able to induce substantial amount of IL-12p70 required for Th1 induction (Supplementary Figure 1C-1E Because pDCs are a primary source of IFN-α in response to influenza virus, which is expressed in a TLR7-dependent manner [17] , we exposed pDC-depleted or total CBMCs to TIV and BCG vaccine. IL-12 secretion remained unchanged for BCG vaccine, but the IFN-α response to TIV was strongly reduced for pDC-depleted CBMCs ( Figure 1C ), correlating with a decrease in expression of T cell-derived IFN-γ ( Figure 1D ). We previously reported the production of IL-12p40 by a small subset of CD2 + CD5 + pDCs in response to live H1N1 PR/8 influenza virus [13] , but we failed to detect any IL-12p40 with CBMCs stimulated by TIV. We conclude that, in addition to BCG vaccine, TIV is able to promote neonatal Th1 responses, albeit with a pDC requirement.
Influenza Virus Vaccine Formulations Can Educate Neonatal pDCs to Promote Th1 Responses
The results described above showed that pDC depletion from CBMCs greatly reduced the IFN-α response to TIV and decreased expression of T-cell-derived IFN-γ, which strongly suggests that pDCs play a critical role in driving the Th1 response in the context of TIV stimulation. Next, we directly addressed the APC functions of neonatal pDCs by studying their effect on Figure 3B) . Importantly, there was no difference between neonatal and adult pDCs in the capacity to induce Th1 (Figure 2A) , consistent with the notion that innate responses of neonatal pDC are intact following certain viral stimulations, as we recently demonstrated [15] . Besides, neonatal pDCs can drive comparable Th1 responses, using either neonatal or adult naive T cells ( Figure 2B ).
It should be mentioned that in the absence of innate activation, neonatal pDCs rapidly underwent apoptosis and could not drive any T-helper cell differentiation. These results clearly indicate that both live and inactivated influenza viruses can activate neonatal pDCs and efficiently drive a Th1 response. 
TLR Triggering of pDCs Can Lead to Either Neonatal Th1 or Th2 Responses
Because TIV activates leukocytes via TLR7 [18] , we next compared the capacity of the TLR7 and TLR9 pathways to activate neonatal pDCs for the induction of Th1 responses. Similar Th1 differentiation was obtained with neonatal pDCs activated by CpGA/TLR9 (Figure 3) . However, CpGB/TLR9, as well as R848 (a TLR7/8 agonist [19] ), mainly induced Th2 differentiation and low levels of IFN-γ, clearly showing that TLR activation of pDCs itself was not sufficient for Th1 priming (Figure 3 ). pDCs were recently shown to promote Th22 cells [20] . In our experimental conditions, only CpGB efficiently induced Th22 cells, but all stimuli failed to induce Th17 cells (Figure 3) . Similar results were obtained with adult pDCs (Supplementary Figure 3) . Analysis of costimulatory molecule expression showed that all stimuli induced similar upregulation of CD40 and 4 naive CD4 + T cells were stimulated with aCD3/CD28 beads at a ratio of 1:1, and, as indicated, recombinant IFN-α (10 3 U/mL) was added to the culture in the presence or absence of 10 μg/mL neutralizing anti-type I IFN receptor antibody or isotype control antibody. Intracellular IFN-γ and interleukin 4 (IL-4) expression was determined following PMA/Ionomycin restimulation. B-D, H1N1/A/PR/8-stimulated plasmacytoid dendritic cell-conditioned medium was used for the differentiation of the aCD3/aCD28 bead-stimulated naive CD4 + T cells. Neutralizing antibodies against type I interferon receptor, IFN-α/β, interleukin 12 (IL-12), tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), CCR5, CXCR3, or isotype control (Iso mAb; 10 μg/mL for each) was added into the culture. At day 6, differentiated T cells were tested for intracellular IFN-γ and IL-4 expression following PMA/Ionomycin restimulation (B). Alternatively, differentiated T cells were stimulated with plate-bound aCD3 and soluble anti-CD28, and IFN-γ and IL-4 expression was determined from the supernatants (D). The ratio of IFN-γ-positive cells from each condition against the isotype antibody control condition was calculated (C). The results are the means ± SD of values for 5 (C) or 4 (D) independent donors. *P < .05 for the comparison with the isotype-control-treated group.
HLA-DR, whereas limited CD80/CD86 upregulation was found following CpGA, H1N1, and TIV stimulation ( Figure 4A ). Th2 conditions were associated with a high level of CD80/CD86 expression and low IFN-α production ( Figure 4B ) following R848 and CpGB activation of pDCs. Under the various conditions described above, pDCs produced similar amounts of TNF-α ( Figure 4B ). Therefore, successful neonatal Th1 was associated with high IFN-α and CD40 induction and poor CD80/CD86 expression on neonatal pDCs.
Influence of IFN-α on Neonatal Th1 Polarization
We next assessed the mechanism involved in IFN-γ cellular immunity induced by activated neonatal pDCs. We first evaluated the influence of type I IFN by differentiating naive neonatal T cells activated by CD3/CD28 beads and cultured with or without IFN-α ( Figure 5A ). Under these conditions, IFN-α shifted T-cell differentiation from IL-4-to IFN-γ-producing T cells, which was blocked by the addition of an anti-type I IFN receptor (IFNAR) antibody. Medium conditioned by virus-activated pDCs also induced neonatal Th1 responses ( Figure 5B-5D ). Following pDC activation by viruses, pDCs are known to produce IFN-α, TNF-α, IL-6, CXCL10, CCL3, and CCL4, but among the blocking antibodies tested, only IFNAR blockade inhibited Th1 priming capacity. We previously showed that CD2 + CD5 + pDCs were producing IL-12p40 by intracellular staining, but IL-12p40 was not detected in the supernatant of activated pDCs, most likely reflecting the paucity of this subset among neonatal pDCs [13] . Consistent with this, IL-12-blocking antibodies failed to modulate the outcome of Th1 differentiation, demonstrating the IL-12 independency of the phenomenon ( Figure 5B-5D ). We conclude that the innate cytokine environment following neonatal pDC activation by viruses shaped Th1 responses through type I IFN.
Neonatal pDCs Efficiently Cross-present Viral Particles to CD8 + T Cells
The induction of cytotoxic T-cell responses via antigen crosspresentation by human pDCs has also emerged as a new target for vaccine design [21] . When neonatal pDCs were loaded with HIV MN AT-2-inactivated viral particles, they were able to promptly cross-present antigen to an HLA-A2-restricted Gag-specific CD8 + T-cell clone, as is seen with adult pDCs, clearly demonstrating the ability of cord blood pDCs to perform cross-presentation, as well ( Figure 6 ). Overall, neonatal pDCs behave as efficient APCs that are capable of activating T-cell immunity and of driving IFN-γ-producing T cells.
DISCUSSION
The age-dependent maturation of the IL-12 response in the context of TLR activation requires the development of alternative strategies for the induction of inflammatory T-cell responses to vaccines and pathogens. After screening for vaccines administered to young infants that could favor Th1 responses, we showed that TIV, which is a poor inducer of neutralizing antibodies in early life, displayed adjuvant properties allowing the differentiation of neonatal T cells into IFN-γ-producing T cells. Initial screen of pediatric vaccines was performed on whole blood to take into account neonatal cellextrinsic and cell-intrinsic factors. TIV but not other viral preparations, such as live MMR vaccine, was able to condition neonatal blood cells for IFN-γ production. Because pDCs are not permissive to measles virus infection, it is possible that a first round of infection of CD46-positive permissive cells would be necessary to produce any effect, which might explain why effects were not seen in our experimental conditions [22, 23] . Induction of neonatal Th1 responses could be achieved through the mobilization of neonatal pDCs and was dependent on type I IFN production, which occurs in response to contaminating RNA material in the commercial TIV preparation. pDCs can promote a large variety of T-helper cell differentiation patterns, depending on their activation context. Early studies showed that human pDCs treated with interleukin 3 and CD40L drive Th2 responses [24] , whereas treatment with CD40L plus influenza A virus can induce Th1 responses in an IL-12-and IFN-α-dependent manner [25] . More recently, thymic stromal lymphopoietin-treated pDCs were shown to promote Foxp3 + T-regulatory cells [26] , while CpGB-activated pDCs also could induce Th22 differentiation in an IL-6-and TNF-α-dependent manner [20] , and TLR7 was shown to activate pDCs to support memory Th17 cells through IL-1β and IL-23 [27] . With regard to influenza A virus [17] , TIV activates the immune system through TLR7 and in a pDC-dependent manner [18] . However, we show that the activation of pDCs through TLR7 by TIV and R848 leads to dominant Th1 and Th2 responses, respectively. Similar results were observed when neonatal DCs are activated by CpGA and CpGB, leading to Th1 and Th2 differentiation, respectively. Under our experimental conditions, we have identified that, following the stimulation of TIV or CpGA, pDC-derived type I IFN was important in priming the differentiation of IFN-γ-producing T cells. On the other hand, CpGB and R848, with the induction of very low levels of IFN-α, mainly promoted neonatal Th2 responses. Interestingly, we show the impairment of R848 in inducing neonatal IL-12p70, which suggests that its incapacity to trigger the IL-12/IFN-γ-pathway in conventional DCs, although this needs to be fully investigated. Under all conditions, neonatal pDCs also induced some IL-22-producing T cells, as was previously reported for adult pDCs [20] .
Finally, antiviral immunity relies critically on the induction of cytotoxic CD8 + T-cell responses requiring direct antigen presentation, as well as cross-presentation by DCs [28] . DCs derived from neonatal monocytes can perform major histocompatibility complex I presentation [29] . The early demonstration of the capacity for pDC cross-presentation in the context of HIV [21] led us to investigate this issue with circulating neonatal pDCs. Although the exact contribution of pDCs in the overall cross-presentation process remains to be clarified [30] , our careful evaluation has shown that neonatal pDCs are fully competent for cross-presentation. Because TIV can induce CD8 + T-cell responses in children as well, cross-presentation is likely to play an important part [31] . We demonstrated that neonatal pDCs can potently participate in innate and adaptive immunity in the context of viral infection, indicating that pDCs may play an active role in protecting neonates from infections. In contrast to early data indicating that pDCs would be poorly effective in early life, we recently showed potent IFN-α responses of neonatal pDC to a large variety of viruses [15] . In line with these observations, we provide evidence that the current inactivated influenza vaccine is able to trigger pDCs to efficiently induce Th1 differentiation. Importantly, we evaluated commercially available vaccines and not laboratory preparations. The Th1 priming capacity of influenza virus-activated neonatal pDCs was correlated with the production of high levels of IFN-α, and we demonstrated with influenza virus that Th1 differentiation occurred in a type I IFN-dependent but IL-12-independent manner. Poliovirus vaccine, as well as other viral vaccines, did not show such potency, in agreement with the Th2 response observed in response to oral poliovirus vaccination [32] . Although replicating viruses were more potent in terms of immune responses, systems biology studies applied to seasonal influenza vaccination highlighted that both TIV and a live attenuated vaccine (LAIV) were able to activate pDC functions in vivo [1] . Adult and >5-year-old children can both develop influenza virus-specific IFN-γ-producing CD4 + T cells [31] . LAIV always demonstrates superior efficacy over TIV [31, 33] . Nevertheless, at ages as young as 6 months, TIV was also shown to induce significant IFN-γ T-cell responses [31] . The limited capacity of TIV in inducing neutralizing antibodies in the very young can be thus distinguished from the adjuvanticity of the vaccine preparation in shaping T-cell responses. Whereas LAIV cannot be administered to very young children, recent safety studies show that TIV is well tolerated starting from 2 months of age [34] . BCG vaccine has been shown to induce bystander adjuvant effects by boosting immune response to other vaccines [16] , but systematic BCG vaccination has been stopped in many developed countries. All other pediatric vaccines fail to promote IFN-γ T-cell responses. The ability of TIV to induce CD4 Th1 responses in very young vaccinated children could be investigated as a proof of concept, using TIV as an adjuvant to potently boost pediatric vaccination toward cellular immunity for other vaccines.
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